Cabometyx for prostate cancer – pro
Results from the COMET-1 Phase III pivotal study with Cabometyx 60 mg tablets in men with mCRPC in patients, who like this patient, had disease progression after treatment with docetaxel as well as Zytiga® (abiraterone acetate tablets) and/or Xtandi® (enzalutamide capsules), showed that the study failed to meet its primary endpoint of demonstrating statistically significant increase in overall survival (OS) compared with prednisone. The median OS with Cabometyx was 11.0 months vs. 9.8 months with prednisone (hazard ratio [HR] 0.90; 95% CI: 0.76, 1.06; P = 0.213). Based on these results, the second Phase III study, COMET-2 was aborted.
References:
Smith M, De Bono J, Sternberg C, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34:3005-3013.
Exelixis. Study of cabozantinib (XL184) versus mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer (COMET-2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2017 April 18]. Available from:
http://www.clinicaltrials.gov/ct2/show/NCT01522443?term=NCT01522443&rank=1. NLM identifier: NCT01522443
(terminated).
NCCN Prostate Cancer 2020